無料レポート プレゼントキャンペーン 実施中 : メールサービスに新規登録いただいた方にご用意した無料レポートをご提供

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙SALE
市場調査レポート

肝硬変の世界市場:2016〜2020年

Global Liver Cirrhosis Market 2016-2020

発行 TechNavio (Infiniti Research Ltd.) 商品コード 357747
出版日 ページ情報 英文 74 Pages
即納可能
価格
本日の銀行送金レート: 1USD=113.41円で換算しております。
Back to Top
肝硬変の世界市場:2016〜2020年 Global Liver Cirrhosis Market 2016-2020
出版日: 2016年05月06日 ページ情報: 英文 74 Pages
概要

肝硬変は、肝臓の組織の損傷などより肝臓の適切な機能が停止する重篤な症状です。長期的なウイルス感染への暴露やアルコールなどの毒素によって引き起こされます。また慢性的な肝炎ウイルスや非アルコール性脂肪性肝炎も肝硬変の原因となります。世界の肝硬変市場は、2016〜2020年にかけ、CAGR4.36%で拡大すると予測されています。

当レポートでは、世界の肝硬変市場の現状と2020年までの成長見通し、市場の動向と課題、地域別動向、主要ベンダーのプロファイルなどをまとめています。

第1章 エグゼクティブサマリー

第2章 当レポートの範囲

第3章 市場調査方法

第4章 イントロダクション

第5章 疾患の概要

  • 疾患の理解
  • 病因
  • 症状
  • 病態生理学
  • 診断
  • 疫学
  • 予防
  • 治療
  • アルコール消費が肝硬変に及ぼす影響

第6章 パイプラインポートフォリオ

  • パイプライン候補情報
  • 治験

第7章 市況

  • 市場概要
  • 市場規模と予測
  • ファイブフォース分析

第8章 分子タイプ別市場セグメンテーション

  • 生物製剤
  • 小分子

第9章 肝硬変の種類別市場セグメンテーション

第10章 肝硬変治療の種類別市場セグメンテーション

  • 肝硬変の原因の治療
  • 肝硬変の合併症の治療

第11章 地域別市場セグメンテーション

  • 南北アメリカ
  • 欧州・中東・アフリカ
  • アジア太平洋地域

第12章 市場促進因子

  • 肝硬変の高い罹患率
  • 技術の進歩
  • 高い医療アンメットニーズ
  • ライフスタイルの変化

第13章 促進因子の影響

第14章 市場の課題

  • 代替療法の使用
  • 薬剤の副作用
  • 患者順守の不徹底
  • 厳しい法規制ガイドライン

第15章 促進因子と課題の影響

第16章 市場動向

第17章 ベンダー環境

  • 競合シナリオ
  • F Hoffmann-La Roche
  • GlaxoSmithKline
  • Gilead Sciences
  • Johnson & Johnson
  • Merck
  • その他の注目すべきベンダー

第18章 付録

第19章 Technavioについて

図表

図表
  • Exhibit 01: Product offerings
  • Exhibit 02: Stages of liver diseases
  • Exhibit 03: Causes of liver cirrhosis
  • Exhibit 04: Diagnosis of liver cirrhosis
  • Exhibit 05: Effect of alcohol consumption on liver cirrhosis
  • Exhibit 06: Pipeline molecules for liver cirrhosis
  • Exhibit 07: Clinical trials by development phase
  • Exhibit 08: Clinical trials by trial status
  • Exhibit 09: Global liver cirrhosis medication market 2015-2020 ($ billions)
  • Exhibit 10: Five forces analysis
  • Exhibit 11: Four main types of liver cirrhosis
  • Exhibit 12: Market share by types of liver cirrhosis
  • Exhibit 13: Types of treatment for liver cirrhosis
  • Exhibit 14: Global liver cirrhosis medication market segment by geography 2015
  • Exhibit 15: Global liver cirrhosis medication market segment by geography 2015-2020 ($ millions)
  • Exhibit 16: Liver cirrhosis medication market in Americas ($ millions)
  • Exhibit 17: Liver cirrhosis medication market in EMEA ($ millions)
  • Exhibit 18: Liver cirrhosis medication market in APAC ($ billions)
  • Exhibit 19: Impact of drivers
  • Exhibit 20: Impact of drivers and challenges
  • Exhibit 21: F Hoffmann-La Roche: Business segmentation 2014 by revenue
  • Exhibit 22: F Hoffmann-La Roche: Business segmentation by revenue 2013 and 2014 ($ billions)
  • Exhibit 23: F Hoffmann-La Roche: Geographical segmentation by revenue 2014
  • Exhibit 24: F Hoffmann-La Roche: YoY growth and revenue of Pegasys 2012-2014 ($ billions)
  • Exhibit 25: F Hoffmann-La Roche: Key takeaways
  • Exhibit 26: GlaxoSmithKline: Business segmentation by revenue 2014
  • Exhibit 27: GlaxoSmithKline: Business segmentation by revenue 2013 and 2014 ($ billions)
  • Exhibit 28: GlaxoSmithKline: Geographical segmentation by revenue 2014
  • Exhibit 29: GlaxoSmithKline: YoY growth and revenue of Epivir 2012-2014 ($ millions)
  • Exhibit 30: Gilead Sciences: Geographical segmentation by revenue 2014
  • Exhibit 31: Gilead Sciences: YoY revenue comparison of Sovaldi 2013-2014 ($ millions)
  • Exhibit 32: Gilead Sciences: YoY growth and revenue of Viread 2012-2014 ($ millions)
  • Exhibit 33: Gilead Sciences: Key takeaways
  • Exhibit 34: Johnson & Johnson: Business segmentation by revenue 2014
  • Exhibit 35: Johnson & Johnson: Business segmentation by revenue 2013 and 2014 ($ billions)
  • Exhibit 36: Johnson & Johnson: Geographical segmentation by revenue 2014
  • Exhibit 37: Johnson & Johnson: YoY growth and revenue of Incivo 2012-2014 ($ millions)
  • Exhibit 38: Johnson & Johnson: YoY revenue growth of Olysio 2012-2014 ($ millions)
  • Exhibit 39: Johnson & Johnson: Key takeaways
  • Exhibit 40: Merck: Business segmentation by revenue 2014
  • Exhibit 41: Merck: Business segmentation by revenue 2013 and 2014 ($ billions)
  • Exhibit 42: Merck: Geographical segmentation by revenue 2014
  • Exhibit 43: Merck: YoY growth and revenue of PegIntron 2012-2014 ($ millions)
  • Exhibit 44: Merck: YoY growth and revenue of Victrelis 2012-2014 ($ millions)
  • Exhibit 45: Merck: Key takeaways
目次
Product Code: IRTNTR8209

About Cirrhosis of the Liver

Cirrhosis of the liver (or liver fibrosis) is a serious condition in which the liver stops functioning properly due to damage and irreversible scarring of the liver tissue. The scarring of the tissue is often caused by long-term exposure to viral infections and toxins such as alcohol. Chronic viral hepatitis and non-alcoholic steatohepatitis can also cause liver cirrhosis. Alcohol-related medications, antiviral medications, and metal chelating agents are used in the treatment of the causes of liver cirrhosis while antibiotics, vitamins, corticosteroids, diuretics, beta-blockers, and laxatives are used for the treatment of the complications of the disease.

Technavio's analysts forecast the global liver cirrhosis therapeutics market to grow at a CAGR of 4.36% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global liver cirrhosis therapeutics market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of prescription, generic, and off-label drugs used in the treatment of liver cirrhosis.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Liver Cirrhosis Therapeutics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • F Hoffman La-Roche
  • GlaxoSmithKline
  • Gilead Sciences
  • Johnson & Johnson
  • Merck

Other Prominent Vendors

  • Bristol-Myers Squibb
  • Conatus Pharmaceuticals
  • Gwo Xi Stem Cell Applied Technology
  • Instituto Grifols
  • Intercept Pharmaceuticals
  • NGM Biopharmaceuticals
  • Norgine
  • Pharmicell
  • Salix Pharmaceuticals
  • Stempeutics Research

Market driver

  • High prevalence of liver cirrhosis
  • For a full, detailed list, view our report

Market challenge

  • Adverse effects of drugs
  • For a full, detailed list, view our report

Market trend

  • Use of off-label drugs
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights

PART 05: Disease overview

  • Understanding the disease
  • Etiology
  • Symptoms
  • Pathophysiology
  • Diagnosis
  • Epidemiology
  • Prevention
  • Treatment
  • Impact of alcohol consumption on liver cirrhosis

PART 06: Pipeline portfolio

  • Information on pipeline candidates
  • Clinical trials for liver cirrhosis

PART 07: Market landscape

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 08: Market segmentation by type of molecule

  • Biologics
  • Small molecules

PART 09: Market segmentation by types of liver cirrhosis

PART 10: Market segmentation by types of liver cirrhosis treatment

  • Medications to treat causes of liver cirrhosis
  • Medications to treat complications of liver cirrhosis

PART 11: Geographical segmentation

  • Liver cirrhosis medication market in Americas
  • Market overview
  • Market size and forecast
  • Liver cirrhosis medication market in EMEA
  • Market overview
  • Market size and forecast
  • Liver cirrhosis medication market in APAC
  • Market overview
  • Market size and forecast

PART 12: Market drivers

  • High prevalence of liver cirrhosis
  • Advances in technology
  • High unmet medical needs
  • Changes in lifestyle

PART 13: Impact of drivers

PART 14: Market challenges

  • Use of alternative therapies
  • Adverse effects of drugs
  • Poor patient adherence
  • Stringent regulatory guidelines

PART 15: Impact of drivers and challenges

PART 16: Market trends

  • Rise in public awareness
  • Increase in R&D
  • Use of off-label drugs
  • Patient assistance programs

PART 17: Vendor landscape

  • Competitive scenario
  • F Hoffmann-La Roche
  • GlaxoSmithKline
  • Gilead Sciences
  • Johnson & Johnson
  • Merck
  • Other prominent vendors

PART 18: Appendix

  • List of abbreviations

PART 19: Explore Technavio

Back to Top